Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.72 |
| ▸ | GAA | P10253 | 2/20 | 0.68 |
| ▸ | TP53 | P04637 | 1/20 | 0.68 |
| ▸ | PKM | P14618 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.52 |
| ▸ | SGMS1 | Q86VZ5 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1287382 | 0.96 | TAAR1 (0.82) | TAAR1ALDH1A1GAATP53PKM | |
| SCHEMBL13889021 | 0.91 | ALDH1A1 (0.81) | TAAR1ALDH1A1GAATP53PKM | |
| SCHEMBL4516002 | 0.88 | TAAR1 (0.70) | TAAR1ALDH1A1GAATP53PKM | |
| SCHEMBL13073499 | 0.86 | TAAR1 (1.00) | TAAR1ALDH1A1GAAPKMMEN1 | |
| SCHEMBL407477 | 0.85 | ALDH1A1 (1.00) | TAAR1ALDH1A1GAATP53PKM | |
| SCHEMBL1287459 | 0.81 | ALDH1A1 (0.74) | TAAR1ALDH1A1GAATP53PKM | |
| SCHEMBL28808214 | 0.81 | ALDH1A1 (0.79) | TAAR1ALDH1A1GAATP53MEN1 | |
| SCHEMBL1287271 | 0.81 | ALDH1A1 (1.00) | TAAR1ALDH1A1GAATP53MEN1 | |
| SCHEMBL3913371 | 0.81 | ALDH1A1 (0.79) | TAAR1ALDH1A1GAATP53PKM | |
| SCHEMBL30375512 | 0.81 | TAAR1 (0.53) | TAAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090093485-A1 | Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases | ASTRAZENECA AB (SE) | 2009-04-09 | — | — | US | disclosed |
| US-20090093485-A1 | Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases | ASTRAZENECA AB (SE) | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093485-A1 | Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases | NR3C1, NR3C2, NR5A1 | TAAR1 569/4885ALDH1A1 2398/4885GAA 3779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.